Phaseline

Targets › PLG

PLG (Plasminogen [Cleaved into: Plasmin): drug programs, companies and trials

9 programs from 9 companies in 62 trials: 22 Phase 4, 21 Phase 3, 16 Phase 2, 3 Phase 1; Other, Cardiovascular, Gastroenterology; next expected readout Dec 2026.

[Plasmin]: Protease which primary function is to degrade fibrin, the main component of blood clots. Also cleaves other components of blood clots like thrombospondin-1/THBS1 and von Willebrand factor (VWF). (UniProt, P00747)

Open in Phaseline: the race on PLG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Health Network, TorontoTopical Tranexamic Acid
Antifibrinolytic agent that inhibits plasminogen activation and fibrinolysis
PLGPhase 4Distal Radius FracturesDec 2026
The First Affiliated Hospital with Nanjing Medical UniversityRecombinant staphylokinase (r-SAK)
Serine protease fibrinolytic enzyme that directly activates plasminogen to plasmin
PLGPhase 4ST Elevation Myocardial InfarctionDec 2026
Massachusetts General HospitalTopical Tranexamic acid
Plasminogen inhibitor
PLGPhase 4Drain Output After Breast Reduction SurgeryMar 2027
Youssef YammineTranexamic acid
Plasminogen inhibitor
PLGPhase 3Hemorrhage LungMar 2028
SupergeneNon-immunogenic recombinant staphylokinase (Fortelyzin®)
Staphylokinase, a plasminogen activator
PLG, PLMNPhase 3Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, AcuteJun 2028
New York Medical CollegeDefibrotide
Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist
ADORA2B, ADORA2A, PLG, ADORA1, F2Phase 2Sickle Cell Disease; Sinusoidal Obstruction SyndromeDec 2026
Jiangsu Jingze BiopharmaceuticalRecombinant Human Truncated Plasmin Injection (JZB32)
Serine protease (truncated plasmin) that cleaves fibrin and other extracellular matrix pro
PLGPhase 2Vitreomacular Traction (VMT)Dec 2027
Children's National Research InstituteAminocaproic Acid
Plasminogen inhibitor; Tissue-type plasminogen activator inhibitor
PLG, PLATPhase 2CraniosynostosisJan 2028
Ascension HealthTranexamic acid
Plasminogen inhibitor
PLGPhase 2Postoperative Blood Loss; Knee Osteoarthritis; Hemorrhage; Melasma …–

Conditions

Postpartum Hemorrhage (3) Trauma Coagulopathy (2) Post Burn Facial Hyperpigmentation (2) ST Elevation Myocardial Infarction (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Distal Radius Fractures (1) Postoperative Blood Loss (1) Knee Osteoarthritis (1) Hemorrhage (1) Melasma (1) Upper Gastrointestinal Bleeding (UGIB) (1)

Modalities

small molecule (6), protein or peptide (3)

Companies

The First Affiliated Hospital with Nanjing Medical University (1) New York Medical College (1) University Health Network, Toronto (1) Ascension Health (1) Jiangsu Jingze Biopharmaceutical (1) Massachusetts General Hospital (1) Supergene (1) Youssef Yammine (1) Children's National Research Institute (1)

Related targets

ADORA2B (1) ADORA2A (1) ADORA1 (1) F2 (1) PLMN (1) PLAT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.